Ascendum Capital
Ascendum Capital is a private equity firm founded in 2020 and based in Hong Kong, China. The firm specializes in healthcare investments, targeting companies involved in innovative MedTech, biotechnology, and other technology sectors related to healthcare. Ascendum Capital aims to accelerate the research and development as well as the commercialization of leading healthcare technologies. Additionally, the firm supports healthcare companies in their expansion efforts or acquisitions, with a particular emphasis on the Chinese market.
Top Stages
4 past transactions
Tingsheng Technology
Series B in 2023
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Valgen Medtech
Series B in 2021
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
EndoWays
Acquisition in 2021
EndoWays is a robotics company specializing in microcatheter technology. Its platform enables interventional radiologists to navigate tortuous anatomy, reducing procedure time and minimizing radiation exposure for both patients and medical staff. Established in 2017, the company is headquartered in Tel Aviv, Israel.
Broncus Technologies
Series C in 2020
Broncus Technologies is a medical technology company specializing in minimally-invasive devices for treating emphysema and other lung diseases. Its flagship product, Exhale, employs Airway Bypass therapy, potentially the first minimally-invasive treatment for severe homogeneous emphysema. Broncus is currently enrolling patients worldwide in its pivotal EASE Trial.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.